CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-CO-105610-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 12 Jun 2014
Amendment
No
General Information
Colombia
Resolución 1250: Por la cual se autoriza el uso (importación y comercialización) a la empresa intervet Colombia LTDA del producto INNOVAX ND SB, vacuna aviar para la enfermedad de Marek y la enfermedad de Newcastle serotipos 2 y 3 virus vivo, vector vivo de la enfermedad de Marek.
ES
09 Apr 2010
No
Subject of the decision, notification, communication or declaration
  • Decision on Pharmaceuticals (Article 5)
LMO identification & risk assessment
  • BCH-LMO-SCBD-105091-1 Living Modified Organism INNOVAX® ND Vaccine
    Intervet do Brasil Veterinária Ltda(INTERVET) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-RA-CO-105609-2 Risk Assessment generated by a regulatory process Uso del producto INNOVAX ND SB, vacuna aviar para la enfermedad de Marek y la enfermedad de Newcastle serotipos 2 y 3 virus vivo, vector vivo de la enfermedad de Marek.
    INNOVAX® ND Vaccine | Production of medical or pharmaceutical compounds (human or animal)
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter